Mauritius: Mauritius Introduces Human Papillomavirus Vaccine for the Prevention of Cervical Cancer
[Government of Mauritius] The human papillomavirus (HPV) vaccination to prevent cervical cancer was launched today at a ceremony at Barkly Government School in Beau Bassin in the presence of the Minister of Health and Quality of Life, Mr Anil Gayan, the Minister of Education, Human Resources, Tertiary Education and Scientific Research, Mrs. Leela Devi Dookun-Luchoomun, and other personalities. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - August 19, 2016 Category: African Health Source Type: news

Parents more likely to support HPV vax requirements if states include opt-out provisions
(American Association for Cancer Research) Parents are more likely to support laws that would make the human papillomavirus vaccine mandatory for school entry if their state offers opt-out provisions, however, the study's lead author cautioned that such opt-out provisions may weaken the effectiveness of the vaccine requirements. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 19, 2016 Category: Infectious Diseases Source Type: news

Gardasil or Meningococcal Vaccine: Which Would Spock Choose?
Negative parental response to the HPV vaccine is often rooted in emotion. Our quick quiz offers you some rational data that could help parents face facts. (Source: ConsultantLive)
Source: ConsultantLive - August 11, 2016 Category: Internal Medicine Authors: Terry Brenneman, MD Tags: Vaccines Source Type: news

FDA Approves Gardasil 9 HPV Vaccine
By Stacy Simon RESOURCES: Cervical cancer resourcesHPV and cervical cancerHuman Papilloma Virus (HPV) VaccinesAmerican Cancer Society recommendations for HPV vaccine by age The US Food and Drug Administration (FDA) has approved Gardasil 9, a new vaccine for human papillomavirus (HPV). The vaccine is expected to become available in February 2015. Gardasil 9 protects against 9 types of HPV, more than the vaccines already on the market, Gardasil and Cervarix. Those vaccines protect against the 2 types of HPV that cause approximately 70% of cervical cancers. (Gardasil also protects against 2 more types that cause genital...
Source: American Cancer Society :: News and Features - August 9, 2016 Category: Cancer & Oncology Tags: Cervical Cancer Prevention/Early Detection Source Type: news

HPV vaccination provides protection for immunocompromised children
A quadrivalent human papillomavirus vaccine provided adequate seroconversion response rates in immunocompromised children, according to Dr. C. Raina MacIntyre, MBBS, PhD, and her associates. In a clinical trial of 59 immunocompromised children aged 5-18, seroconversion rates for HPV types 6, 11,... (Source: Skin and Allergy News)
Source: Skin and Allergy News - August 9, 2016 Category: Dermatology Source Type: news

9-valent, quadrivalent HPV vaccines have comparable safety
The 9-valent human papillomavirus vaccine was well tolerated in 16-26 year olds and had a safety profile comparable to that of the quadrivalent vaccine, according to an analysis of seven phase III... (Source: Pediatric News)
Source: Pediatric News - July 15, 2016 Category: Journals (General) Source Type: news

Big Pharma eyes Bay Area, Boston expansions as it cuts R&D elsewhere
Drug giant Merck & Co. Inc. will cut research jobs at three East Coast sites as it searches for a major Bay Area home to consolidate its cancer and biologics R&D work and hires about 100 scientists. The company (NYSE: MRK) will move into an interim facility in South San Francisco early next year, according to a spokeswoman for the Kenilworth. N.J.-based maker of the Gardasil human papillomavirus vaccine, cancer immunotherapy drug Keytruda and a host of other products. But it is continuing a search… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 13, 2016 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Big Pharma eyes Bay Area, Boston expansions as it cuts R&D elsewhere
Drug giant Merck & Co. Inc. will cut research jobs at three East Coast sites as it searches for a major Bay Area home to consolidate its cancer and biologics R&D work and hires about 100 scientists. The company (NYSE: MRK) will move into an interim facility in South San Francisco early next year, according to a spokeswoman for the Kenilworth. N.J.-based maker of the Gardasil human papillomavirus vaccine, cancer immunotherapy drug Keytruda and a host of other products. But it is continuing a search… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 13, 2016 Category: Biotechnology Authors: Ron Leuty Source Type: news

Big Pharma eyes Bay Area, Boston expansions as it cuts R&D elsewhere
Drug giant Merck & Co. Inc. will cut research jobs at three East Coast sites as it searches for a major Bay Area home to consolidate its cancer and biologics R&D work and hire about 100 scientists. The company (NYSE: MRK) will move into an interim facility in South San Francisco early next year, according to a spokeswoman for the Kenilworth. N.J.-based maker of the Gardasil human papillomavirus vaccine, cancer immunotherapy drug Keytruda and a host of other products. But it is continuing a search… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 12, 2016 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Big Pharma eyes Bay Area, Boston expansions as it cuts R&D elsewhere
Drug giant Merck & Co. Inc. will cut research jobs at three East Coast sites as it searches for a major Bay Area home to consolidate its cancer and biologics R&D work and hire about 100 scientists. The company (NYSE: MRK) will move into an interim facility in South San Francisco early next year, according to a spokeswoman for the Kenilworth. N.J.-based maker of the Gardasil human papillomavirus vaccine, cancer immunotherapy drug Keytruda and a host of other products. But it is continuing a search… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 12, 2016 Category: Biotechnology Authors: Ron Leuty Source Type: news

Reduced HPV Vaccine Dosing Could Be WorthwhileReduced HPV Vaccine Dosing Could Be Worthwhile
The US Food and Drug Administration recommends three doses of the human papillomavirus vaccine (HPV), but recent data suggest that fewer shots might be sufficient. Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - June 24, 2016 Category: Allergy & Immunology Tags: Nursing News Source Type: news

Systematic Review of 58 Publications of Real-World Use of GARDASIL ® Presented at EUROGIN Congress
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " > KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > Studies Published over the Last 10 Years Report Reductions in Cervical Pre-cancers and Other HPV-related Diseases < /p > < /div > < /div > < /di...
Source: Merck.com - Corporate News - June 16, 2016 Category: Pharmaceuticals Tags: Vaccine News Corporate News Latest News #Merck #MRK $MRK EUROGIN Gardasil MSD NYSE:MRK Source Type: news

Systematic Review of 58 Publications of Real-World Use of GARDASIL® Presented at EUROGIN Congress
Dateline City: KENILWORTH, N.J. Studies Published over the Last 10 Years Report Reductions in Cervical Pre-cancers and Other HPV-related Diseases KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that in a systematic review conducted of the global impact and effectiveness of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], substantial reductions we...
Source: Merck.com - Corporate News - June 16, 2016 Category: Pharmaceuticals Tags: Vaccine News Corporate News Latest News #Merck #MRK $MRK EUROGIN Gardasil MSD NYSE:MRK Source Type: news

Cancer-causing HPV plummeted in teens since vaccine, study finds
The human papillomavirus vaccine was first recommended for adolescent girls in the United States in 2006. Since that time, the prevalence of the cancer-causing virus has been dropping among young women, according to a new study. (Source: CNN.com - Health)
Source: CNN.com - Health - March 15, 2016 Category: Consumer Health News Source Type: news

HPV vaccination protects high-risk girls from cervical cancer
Full or partial vaccination with the quadrivalent human papillomavirus vaccine reduced the overall risk of abnormal cervical pathology by 36%, based on data from a retrospective cohort study of just... (Source: Pediatric News)
Source: Pediatric News - March 14, 2016 Category: Journals (General) Source Type: news